Treatment responses for disseminated intravascular coagulation in 25 children treated with recombinant thrombomodulin: A single institution experience

Thrombosis Research

Volumn 130, Issue 6, 2012, Pages

  Yagasaki, Hiroshi ^a   Kato, Maiko ^a   Shimozawa, Katsuyoshi ^a   Hirai, Maiko ^a   Nishikawa, Eri ^a   Okuma, Hirotsugu ^a   Ishii, Wakako ^a   Imai, Yuki ^a   Matsumura, Masaharu ^a   Yonezawa, Ryuta ^a   Yoshikawa, Kayo ^a   Shichino, Hiroyuki ^a   Chin, Motoaki ^a   Mugishima, Hideo ^a  

^a NIHON UNIVERSITY   (Japan)

Author keywords

Children; Disseminated intravascular coagulation; Hematological disorders; Recombinant thrombomodulin; Severe infection

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN; CYCLOSPORIN; D DIMER; FIBRIN; FIBRIN DEGRADATION PRODUCT; PROTEIN C; PROTEINASE INHIBITOR; RECOMBINANT THROMBOMODULIN; RECOMODULIN; STEROID; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLEEDING; BLOOD CLOTTING TEST; CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HEMOPHAGOCYTIC SYNDROME; HUMAN; INFANT; INFECTION; KIDNEY FUNCTION; MALE; MENINGITIS; NEWBORN; PETECHIA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTHROMBIN TIME; PURPURA; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPSIS; THROMBOCYTE; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOMODULIN;

EID: 84870240523     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2012.10.004     Document Type: Article

References (22)

1. M. Franchini, M.N. Di Minno, and A. Coppola Disseminated intravascular coagulation in hematologic malignancies Semin Thromb Hemost 36 2010 388 403
2. M. Levi, M. Schultz, and T. van der Poll Disseminated intravascular coagulation in infectious disease Semin Thromb Hemost 36 2010 367 377
3. M. Levi, C.H. Toh, J. Thachil, and H.G. Watson Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology Br J Haematol 145 2009 24 33
4. H. Wada, H. Asakura, K. Okamoto, T. Iba, T. Uchiyama, and K. Kawasugi Expert consensus for the treatment of disseminated intravascular coagulation in Japan Thromb Res 125 2010 6 11
5. I. Maruyama Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation Thromb Haemost 82 1999 718 721
6. S. Moll, C. Lindley, S. Pescatore, D. Morrison, K. Tsuruta, and M. Mohri Phase I study of a novel recombinant human soluble thrombomodulin, ART-123 J Thromb Haemost 2 2004 1745 1751
7. H. Saito, I. Maruyama, S. Shimazaki, Y. Yamamoto, N. Aikawa, and R. Ohno Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial J Thromb Haemost 5 2007 31 41
8. E. Ogawa, H. Yagasaki, M. Kato, H. Shichino, M. Chin, and H. Mugishima Successful treatment of disseminated intravascular coagulation in a child with acute myelogenous leukaemia using recombinant thrombomodulin Br J Haematol 149 2010 911 912
9. N. Kobayashi, T. Maekawa, M. Takada, H. Tanaka, and H. Gonmori Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan Bibl Haematol 49 1983 265 275
10. S. Niimi, T. Oshizawa, M. Naotsuka, S. Ohba, A. Yokozawa, and T. Murata Establishment of a standard assay method for human thrombomodulin and determination of the activity of the Japanese reference standard Biologicals 30 2002 69 76
11. S. Leteurtre, A. Martinot, A. Duhamel, F. Proulx, B. Grandbastien, and J. Cotting Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study Lancet 362 2003 192 197
12. G.R. Bernard, J.L. Vincent, P.F. Laterre, S.P. LaRosa, J.F. Dhainaut, and A. Lopez-Rodriguez Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 2001 699 709
13. V.M. Ranieri, B.T. Thompson, P.S. Barie, J.F. Dhainaut, I.S. Douglas, and S. Finfer Drotrecogin alfa (activated) in adults with septic shock N Engl J Med 366 2012 2055 2064
14. J. Thachil, C.H. Toh, M. Levi, and H.G. Watson The withdrawal of Activated Protein C from the use in patients with severe sepsis and DIC [Amendment to the BCSH guideline on disseminated intravascular coagulation] Br J Haematol 157 2012 493 494
15. S. Nadel, B. Goldstein, M.D. Williams, H. Dalton, M. Peters, and W.L. Macias Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial Lancet 369 2007 836 843
16. J.F. Dhainaut, S.B. Yan, D.E. Joyce, V. Pettilä, B. Basson, and J.T. Brandt Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation J Thromb Haemost 2 2004 1924 1933
17. J. Kienast, M. Juers, C.J. Wiedermann, J.N. Hoffmann, H. Ostermann, and R. Strauss Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation J Thromb Haemost 4 2006 90 97
18. K. Yamakawa, S. Fujimi, T. Mohri, H. Matsuda, Y. Nakamori, and T. Hirose Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study Crit Care 15 2011 R123
19. N. Kawano, S. Yoshida, N. Ono, D. Himeji, Y. Nagahiro, and S. Kawano Clinical features and outcomes of 35 disseminated intravascular coagulation cases treated with recombinant human soluble thrombomodulin at a single institution J Clin Exp Hematop 51 2011 101 107
20. M. Ohshiro, J. Kuroda, Y. Kobayashi, T. Akaogi, E. Kawata, and N. Uoshima ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin Am J Hematol 87 2012 116 119
21. M. Nakashima, M. Kanamaru, K. Umemura, and K. Tsuruta Pharmacokinetics and safety of a novel recombinant soluble human thrombomodulin, ART-123, in healthy male volunteers J Clin Pharmacol 38 1998 40 44
22. A. Veldman, D. Fischer, M.F. Nold, and F.Y. Wong Disseminated intravascular coagulation in term and preterm neonates Semin Thromb Hemost 36 2010 419 428